KTTA
Pasithea TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary-source support is real but narrow: the 10-K shows $55.2 million of cash at December 31, 2025 with management expecting runway into at least the first half of 2028, while PAS-004 has ongoing cancer and NF1 studies with additional interim data planned through 2026 [#10-K-2026-03-30]. If the company posts credible clinical progress and resolves Nasdaq compliance without heavy damage, the stock has room to re-rate from a depressed base.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Despite runway guidance into at least 1H28, the company says it will require additional capital for full development and commercialization, so dilution risk is deferred rather than removed.
Momentum
83
Value
42
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.75 · Bull $1.40 · Bear $0.30
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $3.00
Why
Momentum83 · Δ7d -
Value42 · Δ7d +0.1
Sentiment70 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
83
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
70
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 83.4 / Value 41.9 / Sentiment 69.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$23.89M
Beta
0.22
Shares Out
23.09M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.35
Rev YoY
-
EPS YoY
+85.8%
Gross Margin
-
Op Margin
-
Net Debt
-$6.92M
Current Ratio
4.02
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology